Caris Life Sciences

Caris Life Sciences is a TechBio company founded in 2008 that works at the intersection of molecular science and artificial intelligence. It develops molecular profiling, blood-based cancer diagnostics and AI-driven analytics for precision oncology, with the aim of helping physicians and patients make more informed treatment decisions. The company describes itself as a pioneer in precision medicine that introduced molecular profiling to the field.

Its technical work spans whole genome sequencing, whole transcriptome sequencing, tumor profiling, genomics and data-driven analytics. Caris ChromoSeq is billed as the world's first combined Whole Genome Sequencing and Whole Transcriptome solution, delivering a comprehensive molecular blueprint of a patient's cancer. MI Profile provides molecular blueprints revealing the unique characteristics of each patient's cancer, while MI Cancer Seek is a blood-based cancer diagnostic. The company operates across oncology, healthcare, precision medicine, cancer diagnostics and biotechnology.

Caris states that it is backed by a team of scientific and medical professionals and describes its culture as driven by innovation, compassion and purpose, with a mission centred on the belief that every patient deserves answers as unique as their DNA.